Europe Ovarian Cancer Diagnostics Market
Taille du marché en milliards USD
TCAC : %
Période de prévision |
2023 –2030 |
Taille du marché (année de référence) |
USD 1,874.16 Billion |
Taille du marché (année de prévision) |
USD 3,093.84 Billion |
TCAC |
|
Principaux acteurs du marché |
>Marché européen du diagnostic du cancer de l'ovaire, par type de produit (instruments, kits et réactifs), type de procédure (test de biopsie, test d'imagerie médicale , test de marqueurs sanguins et test génétique), type de cancer ( cellules germinales , tumeur épithéliale et tumeur des cellules stromales), utilisateur final ( centres de diagnostic du cancer , laboratoires hospitaliers, instituts de recherche et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché européen du diagnostic du cancer de l'ovaire
Le cancer de l'ovaire est un type de cancer qui se forme dans les tissus de l'ovaire (l'une des deux glandes reproductrices féminines dans lesquelles se forment les ovules). La plupart des cancers de l'ovaire sont soit des cancers épithéliaux de l'ovaire (un cancer qui commence dans les cellules à la surface de l'ovaire) soit des tumeurs germinales malignes (un cancer qui commence dans les ovules). Les tests et procédures utilisés pour diagnostiquer le cancer de l'ovaire comprennent l'examen pelvien, les tests d'imagerie, les analyses sanguines, la chirurgie, entre autres. Lors d'un examen pelvien, le médecin insère des doigts gantés dans le vagin et appuie simultanément une main sur l'abdomen afin de sentir (palper) les organes pelviens.
Le marché européen du diagnostic du cancer de l'ovaire devrait croître au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 6,5 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 3 093,84 millions USD d'ici 2030 contre 1 874,16 millions USD en 2022.
Rapport métrique |
Détails |
Période de prévision |
2023 à 2030 |
Année de base |
2022 |
Années historiques |
2021 (personnalisable pour 2020-2016) |
Unités quantitatives |
Chiffre d'affaires en millions USD |
Segments couverts |
Par type de produit (instruments, kits et réactifs), type de procédure (test de biopsie, test d'imagerie médicale, test de marqueurs sanguins et test génétique), type de cancer (cellules germinales, tumeurs épithéliales et tumeurs des cellules stromales), utilisateur final (centres de diagnostic du cancer, laboratoires hospitaliers, instituts de recherche et autres) |
Pays couverts |
Allemagne, France, Royaume-Uni, Italie, Espagne, Pays-Bas, Russie, Suisse, Turquie, Belgique et reste de l'Europe |
Acteurs du marché couverts |
Français F. Hoffmann-La Roche Ltd, Tosoh India Pvt. Ltd., Luminex Corporation, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Ngenebio, Abbott, Siemens Healthcare Private Limited, Myriad Genetics Inc., Bio-Rad Laboratories, Inc., R&D Systems, Inc., Foundation Medicine, Inc., Biosupply Ltd, Lcm Genect Srl, Inex Innovate Private Limited, Abcam Plc., Monobind Inc., Fujirebio, Mp Biomedicals, Biovision Inc., Boster Biological Technology, Biogenix Inc. Pvt. Ltd., Genway Biotech et Lifespan Biosciences, Inc. |
Définition du marché du diagnostic du cancer de l'ovaire en Europe
Ovarian cancer is most common in women between the ages of 50 and 79. It is becoming more prevalent as the world's geriatric population grows and there is a greater emphasis on early detection and treatment, which is expected to accelerate ovarian cancer diagnostic market development. Increasing government investment in raising awareness about early cancer detection as well as increasing health-care spending would also propel business growth. Obesity appears to play a significant role in the development of ovarian cancer. Other lifestyle choices that can raise the risk include smoking, drinking, and not having children. Since ovarian cancer is not easily detectable, women who are at risk of developing the disease must undergo routine testing to identify the disease early, allowing the market to expand.
Europe ovarian cancer diagnostic market is growing in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in ovarian cancer diagnostics and development is further boosting the market growth. However, difficulties in ovarian cancer screening techniques might hamper the growth of the Europe ovarian cancer diagnostic market in the forecast period.
Europe Ovarian Cancer Diagnostics Market Dynamics
Drivers
- Growing Ovarian Cancer Awareness
Growing ovarian cancer awareness has led to an increased demand for timely cancer detection, leading to market growth.
Ovarian cancer is one of the major causes of rising mortality rates among female populations worldwide, which is fuelling market growth over the next five years. Cancer in the ovaries and cysts is becoming more common due to various factors such as environmental factors and genetic mutations.
Ovarian cancer is a type of cancer that affects women’s egg-producing organs, the ovaries. Ovarian cancer is difficult to diagnose because the symptoms are vague and are often detected only after cancer has spread through the stomach and pelvis, making it difficult to cure.
As a result, improved diagnostic processes and techniques are required to determine the cancer stage to treat. Furthermore, the rising mortality rate from ovarian cancer is concerning, emphasizing the importance of early detection so that treatment can be provided.
Due to an increase in awareness about ovarian cancer, it is expected to act as a driving factor for market growth.
- Improved Diagnostic Processes and Techniques
Screening tests and exams are used to detect a disease, such as cancer, in people who do not have any symptoms. There has been a lot of research to develop a screening test for ovarian cancer, but there has not been much success so far. The two tests used most often (in addition to a complete pelvic exam) to screen for ovarian cancer are Transvaginal Ultrasound (TVUS) and the CA-125 blood test.
TVUS is a test that uses sound waves to look at the uterus, fallopian tubes, and ovaries by putting an ultrasound wand into the vagina. It can help find a mass (tumor) in the ovary, but it cannot actually tell if a mass is cancer or benign. When it is used for screening, most of the masses found are not cancer.
The CA-125 blood test measures the amount of a protein called CA-125 in the blood. Many women with ovarian cancer have high levels of CA-125. This test can be useful as a tumor marker to help guide treatment in women known to have ovarian cancer because a high level often goes down if treatment is working. But checking CA-125 levels is not as useful as a screening test for ovarian cancer.
Thus, due to the increase in improved diagnostic processes and techniques, it is expected to act as a driving factor for market growth.
RESTRAINTS
High Cost of Diagnosis
Worldwide, the costs of cancer treatment have increased. Health industries are facing several challenges like medical costs for cancer care. The cost of cancer care in 2010 was USD 124.60 billion which was projected to increase to USD 173.00 billion by 2020 with cancer drug prices and acute hospital care as the main drivers. Hence, the increased cost of diagnostic agents production is hampering the market growth.
Lack of Skilled Professionals
Healthcare professionals involved in the diagnostic process have an obligation and ethical responsibility to employ clinical reasoning skills, evaluate, and manage a patient's medical problems. When a diagnosis is accurate and made in a timely manner, a patient has the best opportunity for a positive health outcome because clinical decision-making will be tailored to a correct understanding of the patient's health problem. The lack of skilled professionals may hinder the recovery process of the patient and thus, may hamper the market growth.
OPPORTUNITIES
Increasing Healthcare Expenditure for Cancer Diagnosis and Treatment
Across the globe, R&D activities are escalating owing to public health expenditure with economic performances whereas, the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of R&D opportunities. It is anticipated to upsurge the demand for ovarian cancer diagnostics.
Increasing healthcare expenditure for cancer treatment also helps patients to take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their own care), government expenditure, and sources including health insurance and activities by Non-Governmental Organizations (NGOs). Due to this increasing healthcare expenditure for cancer treatment, it acts as an opportunity for market growth.
CHALLENGES
Strict Regulations and Standards for the Approval and Commercialization of Cancer Diagnostic Products
The stringent regulations for commercialization of any product in the market are proving to be a big challenge for manufacturers of cancer diagnostic products in the U.S. and European region. Every country has its own regulations and has a different body for regulatory procedures.
The regulatory requirement for approvals of marketing as well as the declaration of conformity and the time required for regulatory review may vary for different products. The company which fails to get regulatory approval harms the business because without getting approval on the products, manufacturers are not able to launch their product in the market and for this reason, strict regulations and standards for the approval and commercialization of cancer diagnostic products act as a restraining factor for market growth.
Recent Developments
- In November 2022, Myriad genetics Inc. announced that it has acquired Gateway Genomics, LLC, The acquisition strengthens Myriad Genetics’ portfolio of Women’s Health products, expanding access to personalized genetic tests during the reproductive stage of a women’s life and beyond. With SneakPeek, Myriad now serves women earlier in their pregnancy, providing data-driven genetic insights through their lifetime with the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Score for all ancestries, this will help the company to increase their revenue.
- In October 2022, Quest Diagnostics announced the new phase of collaboration with Decode health, in the starting phase of collaboration, the two parties developed RNA (transcriptome) sequencing capabilities based on both parties' next-generation sequencing, analytics and clinical expertise. The collaboration is significant as biomarker-based data can help reduce the time and cost of developing novel diagnostic tests and identifying new drug targets for different types of cancers (breast, prostate and ovarian cancer). This collaboration helps the company to find innovative paths in the field of R&D and increases the Europe presence of the company.
Europe Ovarian Cancer Diagnostics Market Scope
Europe ovarian cancer diagnostics market is segmented into product type, procedure type, cancer type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Kits and Reagents
On the basis of product type, Europe ovarian cancer diagnostics market is segmented into instruments and kits and reagents.
Procedure Type
- Blood Markers Testing
- Medical Imaging Test
- Biopsy Tests
- Genetic Testing
On the basis of procedure type, Europe ovarian cancer diagnostics market is segmented into blood markers testing, medical imaging test, biopsy tests and genetic testing
Cancer Type
- Epithelial Tumor
- Germ Cell
- Stromal Cell Tumor
On the basis of cancer type, Europe ovarian cancer diagnostics market is segmented into epithelial tumor, germ cell and stromal cell tumor
End User
- Cancer Diagnostic Centers
- Hospital Laboratories
- Research Institutes
- Others
On the basis of end user, Europe ovarian cancer diagnostics market is segmented into cancer diagnostic centers, hospital laboratories, research institutes and others
Europe Ovarian Cancer Diagnostics Market Regional Analysis/Insights
Europe ovarian cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, procedure type, cancer type and end user, as referenced above.
The countries covered in this market report are Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and Rest of Europe.
Germany is dominating the Europe ovarian cancer diagnostics market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence and incidence of neurological disorders in the region, and growing R&D investments and the launch of new products are boosting the market
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Europian brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Ovarian Cancer Diagnostics Market Share Analysis
The ovarian cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ovarian cancer diagnostics market.
Français Certains des principaux acteurs opérant sur le marché européen du diagnostic du cancer de l'ovaire sont F. Hoffmann-la roche ltd, Tosoh india pvt. Ltd., Luminex corporation, Quest diagnostics incorporated, Thermo fisher scientific Inc., Ngenebio, Abbott, Siemens healthcare private limited, Myriad genetics Inc., Bio-rad laboratories, Inc., R&d systems, Inc., Foundation medicine, Inc., Biosupply ltd, Lcm genect srl, Abcam plc., Monobind Inc., Fujirebio, Mp biomedicals, Biovision Inc., Boster biological technology, Genway biotech et Lifespan biosciences, Inc entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS
5 INDUSTRY INSIGHTS
5.1 CONCLUSION
6 REGULATIONS OF THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING OVARIAN CANCER AWARENESS
7.1.2 IMPROVED DIAGNOSTIC PROCESSES AND TECHNIQUES
7.1.3 INCREASE IN NUMBER OF NEW CASES EVERY YEAR
7.1.4 IMPROVED IMAGING TECHNIQUES
7.2 RESTRAINS
7.2.1 HIGH COST OF DIAGNOSIS
7.2.2 ADVERSE EFFECTS OF THE TREATMENT
7.3 OPPORTUNITIES
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 LACK OF SKILLED PROFESSIONALS
8 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 KITS AND REAGENTS
9 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE
9.1 OVERVIEW
9.2 BLOOD MARKERS TESTING
9.3 MEDICAL IMAGING TEST
9.4 BIOPSY TEST
9.5 GENETIC TESTING
10 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 EPITHELIAL TUMOR
10.3 GERM CELL
10.4 STROMAL CELL TUMOR
11 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 CANCER DIAGNOSTIC CENTERS
11.3 HOSPITAL LABORATORIES
11.4 RESEARCH INSTITUTES
11.5 OTHERS
12 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 RUSSIA
12.1.7 TURKEY
12.1.8 BELGIUM
12.1.9 NETHERLANDS
12.1.10 SWITZERLAND
12.1.11 REST OF EUROPE
13 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 F. HOFFMANN-LA ROCHE LTD
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 TOSOH INDIA PVT. LTD.
15.2.1 COMPANY SNAPSHOT
15.2.2 COMPANY SHARE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 LUMINEX CORPORATION (2022)
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 QUEST DIAGNOSTICS INCORPORATED (2022)
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 THERMO FISHER SCIENTIFIC INC
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 ABCAM PLC (2022)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 1.7.4 RECENT DEVELOPMENT
15.8 BIOSUPPLY LTD
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIO-RADBIO LABORATORIES
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIOVISION INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 BIOGENIX INC. PVT. LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 BOSTER BIOLOGICAL TECHNOLOGY
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 FOUNDATION MEDICINE
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 FUJIREBIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 GENWAY BIOTECH
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 INEX INNOVATIVE PRIVATE LIMITED
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 LCM GENETIC SRL
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 LIFESPAN BIOSCIENCES, INC
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.19 MP BIOMEDICALS
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 MONOBIND INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.21 MYRIAD GENETICS, INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 NGENEBIO
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENTS
15.23 R&D SYSTEMS, INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENT
15.24 SIEMENS MEDICAL SOLUTIONS
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 24-MONTH EPISODE-OF-CARE COSTS FOR EARLY-STAGE AND LATE-STAGE CANCERS BY PAYER (USD BILLION)
TABLE 2 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE KITS AND REAGENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE BLOOD MARKERS TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 EUROPE MEDICAL IMAGING TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE BIOPSY TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE GENETIC TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE EPITHELIAL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE GERM CELL IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE STROMAL CELL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE CANCER DIAGNOSTIC CENTERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE HOSPITAL LABORATORIES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE RESEARCH INSTITUTES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE OTHERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 20 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 21 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 22 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 24 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 25 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 26 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 27 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 28 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 29 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 30 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 31 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 32 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 33 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 34 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 35 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 36 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 37 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 38 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 39 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 40 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 42 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 43 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 44 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 46 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 47 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 50 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 54 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 55 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 58 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 59 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 60 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 62 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 63 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 66 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 67 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 2 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : DROC ANALYSIS
FIGURE 4 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID
FIGURE 8 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT OVARIAN CANCER IS EXPECTED TO DRIVE THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2030
FIGURE 12 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET IN 2022 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET
FIGURE 14 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2022
FIGURE 19 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, CAGR (2023-2030)
FIGURE 21 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, LIFELINE CURVE
FIGURE 22 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 23 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 25 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 26 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 31 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 32 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 35 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.